SurgaColl™’s innovative products CondroColl and HydroxyColl are based on a suite of common-platform technologies developed by the Tissue Engineering Research Group (TERG) at the RCSI since its foundation in 2004. These technologies offer product opportunities immediately in the field of bone and cartilage tissue regeneration and further potential for a growing product portfolio in the future. Research is ongoing into future enhancements of the scaffold technologies to facilitate the incorporation of pharmacological agents (TheraColl™) and into exciting new surgical innovations for the repair of a range of human tissue including cardiac (CardioColl™) and dental (DentaColl™) tissue.

Click here to read more about ChondroColl

Click here to read more about HydroxyColl